Reporte zur Charge CUS9282

Symptomtext

Dose 5: Moderna; Dose 4/dose 3/dose 2/dose 1: Pfizer; COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient. A 64-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), on 07Feb2021 as dose 1, single (Lot number: EL9264), in left arm, on 01Mar2021 as dose 2, single (Batch/Lot number: unknown), in left arm, on 30Sep2021 as dose 3 (booster), single (Lot number: 30155BA), in left arm and on 31May2022 as dose 4 (booster), single (Lot number: CUS9282) at the age of 62 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 24Oct2022 as dose 5 (booster), single (Lot number: 059F2219), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known allergies: Penicillin" (unspecified if ongoing). There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Sep2023, outcome "unknown" and all described as "COVID 19 Treatment"; INTERCHANGE OF VACCINE PRODUCTS (medically significant), outcome "unknown", described as "Dose 5: Moderna; Dose 4/dose 3/dose 2/dose 1: Pfizer". Therapeutic measures were taken as a result of drug ineffective, covid-19 included paxlovid treatment from 23Sep2023 to 27Sep2023. The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300316280 same patient, different drug/AE;